Error loading player: No playable sources found

89837

Plenary Session 6 - Fireside Chat: Evolution of Cell and Gene Therapy

Date
June 12, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Join us for an engaging fireside chat delving into the revolutionary landscape of cell and gene therapy. This interactive session will feature esteemed experts at the forefront of the industry, offering insights into the latest advancements, challenges, and future prospects shaping this rapidly evolving field. 


From pioneering research to transformative clinical applications, our panelists will explore the profound impact of cell and gene therapies on human health. Discussions will encompass breakthrough technologies, innovative treatment modalities, regulatory considerations, and the pivotal role of collaboration in driving progress. 


Through candid conversations and real-world experiences, attendees will gain invaluable perspectives on navigating the dynamic landscape of cell and gene therapy. Whether you're a seasoned professional, researcher, regulatory professional, or enthusiast, this fireside chat promises to ignite curiosity, foster connections, and inspire the next wave of innovation in biomedicine. 


Panel Members:


Michael LehmickeAlliance for Regenerative Medicine


Sarah PitluckSP Consulting


Joseph Tarnowski, CHO Plus, Inc.


Related Products

Thumbnail for Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines
Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines
Genome editing is a tool that enables a new generation of medicines by directly targeting with high precision the genetic cause of a disease. It also allows for immune evasion and prevents microenvironment responses: concepts vital to more potent, off the shelf, cell, and gene therapies…
Thumbnail for Plenary Session 1 - Genetic Modification Technologies for Cell-based Gene Therapies
Plenary Session 1 - Genetic Modification Technologies for Cell-based Gene Therapies
In addition to the now well-known CAR T (chimeric antigen receptor T cells) and HSC (CD34+ hematopoietic stem cells) cell-based gene therapies, there are several other modes of gene modification as well as cell types already approved and on the horizon…
Thumbnail for Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Our ability to treat diseases previously untreatable through the delivery of adeno-associated virus (AAV)-based gene therapies has been a tremendous advancement in pharmaceutical development…